



6138704

15W

PTO/SB/21 (02-04)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

**TRANSMITTAL  
FORM**

(to be used for all correspondence after initial filing)

<b>TRANSMITTAL FORM</b>  (to be used for all correspondence after initial filing)	Application Number	10/806852	
	Filing Date	March 23, 2004	
	First Named Inventor	David Rueger	
	Art Unit	N/A	
	Examiner Name	Not Yet Assigned	
Total Number of Pages in This Submission	1	Attorney Docket Number	JJJ-P02-511

**ENCLOSURES (Check all that apply)**

<input type="checkbox"/> Fee Transmittal Form <input type="checkbox"/> Fee Attached <input type="checkbox"/> Amendment/Reply <input type="checkbox"/> After Final <input type="checkbox"/> Affidavits/declaration(s) <input type="checkbox"/> Extension of Time Request <input type="checkbox"/> Express Abandonment Request <input checked="" type="checkbox"/> Information Disclosure Statement <input type="checkbox"/> Certified Copy of Priority Document(s) <input type="checkbox"/> Response to Missing Parts/Incomplete Application <input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53	<input type="checkbox"/> Drawing(s) <input type="checkbox"/> Licensing-related Papers <input type="checkbox"/> Petition <input type="checkbox"/> Petition to Convert to a Provisional Application <input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address <input type="checkbox"/> Terminal Disclaimer <input type="checkbox"/> Request for Refund <input type="checkbox"/> CD, Number of CD(s) _____	<input type="checkbox"/> After Allowance communication to Technology Center (TC) <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences <input type="checkbox"/> Appeal Communication to TC (Appeal Notice, Brief, Reply Brief) <input type="checkbox"/> Proprietary Information <input type="checkbox"/> Status Letter <input checked="" type="checkbox"/> Other Enclosure(s) (please identify below): SB/08 Form
<b>Remarks</b>		

**SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT**

Firm or Individual name	ROPES & GRAY LLP Erika Takeuchi - 55,661
Signature	
Date	June 29, 2004

I hereby certify that this correspondence is being deposited with the U.S. Postal Service as Express Mail, Airbill No. ED 190305638US, in an envelope addressed to: MS Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date shown below.

Dated: June 29, 2004 Signature: Linda Blake (Linda Blake)

I hereby certify that this correspondence is being deposited with the U.S. Postal Service as Express Mail, Airbill No. ED 190305638US, in an envelope addressed to: MS Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date shown below.

Dated: June 29, 2004

Signature: Linda Blake

(Linda Blake)

Docket No.: JJJ-P02-511  
(PATENT)



**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

in re Patent Application of:  
Rueger et al.

Confirmation No.: N/A

Application No.: 10/806852

Art Unit: N/A

Filed: March 23, 2004

Examiner: Not Yet Assigned

For: METHODS AND COMPOSITIONS FOR  
THE TREATMENT OF MOTOR NEURON  
INJURY AND NEUROPATHY

June 29, 2004

**INFORMATION DISCLOSURE STATEMENT (IDS)**

MS Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Dear Sir:

Pursuant to 37 CFR 1.56, 1.97 and 1.98, the attention of the Patent and Trademark Office is hereby directed to the references listed on the attached PTO/SB/08. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the references be made of record therein and appear among the "References Cited" on any patent to issue therefrom.

This Information Disclosure Statement is filed before the mailing date of a first Office Action on the merits as far as is known to the undersigned (37 CFR 1.97(b)(3)).

Copies of the references on the PTO/SB/08 are not provided.

Pursuant to 37 C.F.R. 1.98(d)(1), those patent(s) or publication(s) which are marked with a double asterisk (\*\*) next to the Cite No. in the attached form PTO/SB/08 are not supplied because they were previously cited by or submitted to the Office in a prior application number 08/937,755, filed September 25, 1997, which is relied upon in this application for an earlier filing date under 35 U.S.C. §120.


In accordance with 37 CFR 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information as defined in 37 CFR 1.56(a) exists. In accordance with 37 CFR 1.97(h), the filing of this Information Disclosure statement shall not be construed to be an admission that any patent, publication or other information referred to therein is "prior art" for this invention unless specifically designated as such.

It is submitted that the Information Disclosure Statement is in compliance with 37 CFR 1.98 and the Examiner is respectfully requested to consider the listed references.

Applicants believe no fee is due with this submission. However, if a fee is due, the Director is hereby authorized to charge any deficiency in the fees filed, asserted to be filed or which should have been filed herewith (or with any paper hereafter filed in this application by this firm) to our Deposit Account No. 18-1945, under Order No. JJJ-P02-511. A duplicate copy of this paper is enclosed.

Dated: June 29, 2004

Respectfully submitted,

By   
Erika Takeuchi

Registration No.: 55,661  
ROPES & GRAY LLP  
45 Rockefeller Plaza  
New York, New York 10111-0087  
(212) 497-3625  
(212) 497-3650 (Fax)  
Attorneys/Agents For Applicant



PTO/SB/08a/b (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)				<b>Complete if Known</b>	
				Application Number	10/806852
				Filing Date	March 23, 2004
				First Named Inventor	David Rueger
				Art Unit	N/A
				Examiner Name	Not Yet Assigned
Sheet	1	of	3	Attorney Docket Number	JJJ-P02-511

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	Document Number Number-Kind Code <sup>2</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	AA**	US-5,108,989	04-28-1992	AMENTO et al.	

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		Country Code <sup>3</sup> -Number <sup>4</sup> -Kind Code <sup>5</sup> (if known)				
	BA**	WO 84/01106	03-29-1984			
	BB**	WO 92/15323	09-17-1992			
	BC**	WO 94/03200	02-17-1994			
	BD**	WO 95/05846	03-02-1995			
	BE**	WO 95/06656	03-09-1995			
	BF**	WO 95/10611	04-20-1995			

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. \*\*CITE NO.: Those patent(s) or publication(s) which are marked with a double asterisk (\*\*) next to the Cite No. are not supplied because they were previously cited by or submitted to the Office in a prior application relied upon in this application for an earlier filing date under 35 U.S.C. 120. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.		T <sup>2</sup>
	CA**	AEBISCHER, et al. (1989), "Basic Fibroblast Growth Factor Released From Synthetic Guidance Channels Facilitating Peripheral Nerve Regeneration Across Long Nerve Gaps," 23 J. Neurosci. Res. 282-289.		
	CB**	BARDE (1989), "Trophic Factors and Neuronal Survival," 2 Neuron 1525-1534.		
	CC**	BASLER, et al., (1993), "Control of Cell Pattern in the Neural Tube: Regulation of Cell Differentiation by dorsalin-1, a Novel TGFβ Family Member", 73 Cell, 687-702.		
	CD**	CARSWELL (1993), "The Potential for Treating Neurodegenerative Disorders with NGF-Inducing Compounds," 124 Exp. Neurol. 36.		
	CE**	DE KONINCK, et al. (1993), "NGF Induced Neonatal Rat Sensory Neurons to Extend Dendrites in Culture After Removal of Satellite Cells," 13 J. Neurosci. 577-585.		
	CF**	DEININGER, et al. (1995), "Detection of Two Transforming Growth Factor-β-Related Morphogens, Bone Morphogenetic Proteins -4 and 05, in RNA of Multiple Sclerosis and creutzfeldt-Jakob Disease Lesions," 90 Acta Neuropathol. 76-79.		
	CG**	DEDHAR, et al., (1993), "Differential Regulation of Expression of Specific Integrin Receptors by Nerve Growth Factor and Transforming Growth Factor β1 During Differentiation of Human Neuroblastoma Cells", 1(1): Molecular and Cellular Differentiation, 1-20.		
	CH**	EBENDAL (1992), "Function and Evolution in the NGF Family and Its Receptors," 32 J. Neurosci. Res. 461.		
	CI**	EBENDAL, et al. (1991) "Human Nerve Growth Factor: Biological and Immunological Activities, and Clinical Possibilities in the Neurodegenerative Disease," Plasticity and Regeneration of the Nervous System 207-225 (Timeras, et al., eds. Plenum Press NY).		
	CJ**	FRIEDLANDER, et al. (1986), "Nerve Growth Factor Enhances Expression of Neuron-Blia Cell		

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

Substitute for form 1449A/B/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(Use as many sheets as necessary)</i>				<b>Complete if Known</b>	
				Application Number	10/806852
				Filing Date	March 23, 2004
				First Named Inventor	David Rueger
				Art Unit	N/A
				Examiner Name	Not Yet Assigned
Sheet	2	of	3	Attorney Docket Number	JJJ-P02-511

		Adhesion Molecule in PC12 Cells," 102 J.C.B. 413-419.	
	CK**	GASH, et al. (1996), "Functional Recovery in Parkinsonian Monkeys Treated with GDNF," 380 Nature 252-255.	
	CL**	GROSS, et al. (1993), "Transforming Growth Factor-B1 Reduces Infarct Size After Experimental Cerebral Ischemia in a Rabbit Model," 24 Stroke 558-562.	
	CM**	HEFTI, et al. (1993), "Pharmacology of Nerve Growth Factor in the Brain," 24 Adv. in Pharmacol. 239-273.	
	CN**	JACKOWSKI, et al. (1995), "Neural Injury Repair: Hope For The Future As Barrier To Effective CNS Regeneration Become Clearer," 9 Brit. J. Neurosurgery, 303-317.	
	CO**	Jones, et al. (1991), "Involvement of Bone Morphogenetic Proteins..." 111 Development 2:531-542.	
	CP**	LEE (1991), "Expression of Growth/Differentiation Factor 1 in the Nervous System: Conservation of a Bicistronic Structure," 88 Proc. Natl. Acad. Sci USA, 4250-4254.	
	CQ**	LEFER, et al (1992), "Anti-Ischaemic and Endothelial Protective Actions of Recombinant Human Osteogenic Protein (hOP-1)," J. Mol. Cell. Card 24:585-593.	
	CR**	LEIN, et al. (1995), "Osteogenic Protein-1 Induces Dendritic Growth in Rat Sympathetic Neurons in Vitro," 15 Neuron 597-605.	
	CS**	LEIN, et al. (1989), "Laminin and a Basement Membrane Extract Have Different Effects on Axonal and Dendritic Outgrowth From Embryonic Rat Sympathetic Neurons in Vitro," 136 Dev. Biol. 330-345.	
	CT**	LEROUX, et al (1994), "Regional Differences in Glial-Derived Factors That Promote Dendritic Outgrowth From Mouse Cortical Neurons In Vitro," 14 J. Neurosci. 8:4639-4655.	
	CU**	LUNDBORG (1987), "Nerve Regeneration and Repair," 58 Acta. Orthop. Scand. 145-169.	
	CV**	PERIDES, et al. (1995), "Neuroprotective Effect of Human Osteogenic Protein 1 in a Rat Model of Cerebral Hypoxia/Ischemia," 187 Neurosci. Lett. 21-24.	
	CW**	PURVES, et al. (1988), "Trophic Regulation of Nerve Cell Morphology and Innervation in the Autonomic Nervous System," 336 Nature 123-128.	
	CX**	REISSMAN, et al. (1996), "Involvement of Bone Morphogenetic Protein-4 and Bone Morphogenetic Protein-7 In The Differentiation of the Adrenergic Phenotype In Developing Sympathetic Neurons," 122 Development 2079-2088.	
	CY**	ROUBIN, et al (1990), "Modulation of NCAM Expression by Transforming Growth Factor-Beta, Serum, and Autocrine Factors," 111 J. Cell Biol. 673-684.	
	CZ**	SADD, et al. (1991), "Astrocyte-Derived TGF-B2 and NGF Differentially Regulate Neural Recognition Molecule Expression by Cultured Astrocytes," J. Cell Biol. 2473-483.	
	CA1**	SASAI, et al. (1995), "Regulation of Neural Induction by the Chd and Bmp-4 Antagonistic Patterning Signals in Xenopus," Nature 367:333-356.	
	CB1**	SCHUBERT, et al., (1990) "Activin is a Nerve Cell Survival Molecule", Nature, 344:868:870.	
	CC1**	SHAH, et al. (1995), "Alternative Neural Crest Cell Fates Are Instructively Promoted by TGF-B Superfamily Members," 85 Cell 331-343.	
	CD1**	SNIDER (1988), "Nerve Growth Factor Enhances Dendritic Arborization of Sympathetic Ganglion Cells in Developing Mammals," 8 J. Neurosci. 2628-2634.	
	CE1**	Stromberg, et al. (1993), "Glial Cell Line-Derived Neurotrophic Factor is Expressed in the Developing but Not Adult Striatum and Stimulates Developing Dopamine Neurons in vivo," 124 Exp. Neurol. 401-412.	
	CF1**	TOMAC, et al. (1995), "Protection and Repair of the Nigrostriatal Dopaminergic System by GDNF in vivo," 373 Nature 335-346.	
	CG1**	WILSON, et al. (1995), "Induction of Epidermis and Inhibition of Neural Fate by Bmp-4," 376 Nature 331-333.	
	CH1**	WITHERS, et al. (1996), "Receptivity of Osteogenic Protein-1 (P-1) - Induced Dendrites to Axonal Innervation," Society for Neuroscience, meeting abstract.	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(Use as many sheets as necessary)</i>				<b>Complete if Known</b>	
				Application Number	10/806852
				Filing Date	March 23, 2004
				First Named Inventor	David Rueger
				Art Unit	N/A
				Examiner Name	Not Yet Assigned
Sheet	3	of	3	Attorney Docket Number	JJJ-P02-511

	CI1**	WITHERS, et al. (1995), "Osteogenic Protein-1 (OP-1) Induces Dendritic Growth and Branching in Cultured Hippocampal Neurons", Society for Neuroscience, meeting abstract.	
	CJ1**	RUDINGER, (1976), Peptide Hormones, ed. Parsons, Univ. Park Press, p. 1-7.	
	CK1**	VARLEY, et al., (1995) Developmental Dynamics 203:434-447.	
	CL1**	The Merck Manual of Diagnosis and Therapy, 16th ed., (editor-in-chief Berkow), p. 1512-1513.	
	CM1* *	GUO, et al. (1998), "Osteogenic protein-1 and related bone morphogenetic proteins regulate dendritic growth and the expression of microtubule-associated protein-2 in rat sympathetic neurons," Neuroscience Letters 245 131-134.	

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--



Application No. (if known): 10/806852

Attorney Docket No.: JJJ-P02-511

## Certificate of Express Mailing Under 37 CFR 1.10

I hereby certify that this correspondence is being deposited with the United States Postal Service as Express Mail, Airbill No. ED 190305638 US in an envelope addressed to:

MS Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

on June 29, 2004  
Date

Linda Blake

Signature

Linda Blake

Typed or printed name of person signing Certificate

Note: Each paper must have its own certificate of mailing, or this certificate must identify each submitted paper.

IDS (Citation) by Applicant (3 pages)